IL120264A0 - Method of reducing tissue damage associated with non-cardiac ischemia - Google Patents
Method of reducing tissue damage associated with non-cardiac ischemiaInfo
- Publication number
- IL120264A0 IL120264A0 IL12026497A IL12026497A IL120264A0 IL 120264 A0 IL120264 A0 IL 120264A0 IL 12026497 A IL12026497 A IL 12026497A IL 12026497 A IL12026497 A IL 12026497A IL 120264 A0 IL120264 A0 IL 120264A0
- Authority
- IL
- Israel
- Prior art keywords
- tissue damage
- cardiac ischemia
- damage associated
- reducing tissue
- ischemia
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
- C12Y101/01021—Aldehyde reductase (1.1.1.21), i.e. aldose-reductase
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1270796P | 1996-02-29 | 1996-02-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL120264A0 true IL120264A0 (en) | 1997-06-10 |
Family
ID=21756300
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12026497A IL120264A0 (en) | 1996-02-29 | 1997-02-20 | Method of reducing tissue damage associated with non-cardiac ischemia |
Country Status (14)
Country | Link |
---|---|
US (1) | US6127367A (de) |
EP (1) | EP0792643B1 (de) |
JP (1) | JPH09316003A (de) |
KR (1) | KR970061252A (de) |
CN (1) | CN1081460C (de) |
AT (1) | ATE216239T1 (de) |
AU (1) | AU724327B2 (de) |
CA (1) | CA2198564C (de) |
DE (1) | DE69711972T2 (de) |
DK (1) | DK0792643T3 (de) |
ES (1) | ES2172748T3 (de) |
IL (1) | IL120264A0 (de) |
PT (1) | PT792643E (de) |
ZA (1) | ZA971717B (de) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0982306A3 (de) * | 1998-08-21 | 2000-07-05 | Pfizer Products Inc. | Polymorph von Zopolrestat Monohydrat |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
WO2002098421A1 (en) * | 2001-06-05 | 2002-12-12 | University Of Maryland, Baltimore | Novel treatment for neurological and psychiatric disorders |
US7196085B2 (en) | 2002-04-30 | 2007-03-27 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
US20110092566A1 (en) * | 2004-11-19 | 2011-04-21 | Srivastava Satish K | Treatment of cancer with aldose reductase inhibitors |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
EP1961420B1 (de) * | 2005-12-16 | 2012-07-25 | Sanwa Kagaku Kenkyusho Co., Ltd | Wirkstoff zur prävention oder behandlung von akutem nierenversagen |
CA2642933A1 (en) * | 2006-02-20 | 2007-08-30 | Sanwa Kagaku Kenkyusho Co., Ltd. | Prophylactic or therapeutic agent for cerebral ischemia or cerebral ischemic reperfusion injury in stroke |
TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮(phthalazinone)衍生物 |
EP2110141B1 (de) * | 2007-01-31 | 2013-04-03 | Sanwa Kagaku Kenkyusho Co., Ltd | Wirkstoff zum schutz der retinanerven oder der sehnerven |
EP2848252A3 (de) | 2007-03-23 | 2015-06-17 | The Board of Regents of the University of Texas System | Aldose-Reduktase-Inhibitoren zur Behandlung von Uveitis |
US7981890B2 (en) | 2007-09-14 | 2011-07-19 | Astrazeneca Ab | Phthalazinone derivatives |
BRPI0817537B1 (pt) | 2007-10-17 | 2022-04-05 | Kudos Pharmaceuticals Limited | 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona, método para obtê-lo, composição farmacêutica compreendendo o mesmo, bem como usos terapêuticos do dito composto |
WO2009062309A1 (en) * | 2007-11-15 | 2009-05-22 | Universite Laval | Methods for the regulation of the prostaglandin f synthase (pgfs) activity of akr1b1 and uses thereof |
UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
US20090270490A1 (en) * | 2008-04-24 | 2009-10-29 | The Board Of Regents Of The University Of Texas System | Methods involving aldose reductase inhibition |
HRP20161154T4 (hr) | 2008-10-07 | 2023-09-29 | Kudos Pharmaceuticals Limited | Farmaceutska formulacija 514 |
CA2822672C (en) | 2010-12-23 | 2018-06-05 | The Board Of Regents Of The University Of Texas System | Methods for treating copd |
WO2018075192A1 (en) | 2016-10-19 | 2018-04-26 | Spectrum Brands, Inc. | Portable steam generator base for iron |
US20240033263A1 (en) | 2021-03-18 | 2024-02-01 | Banavara MYLARI | Combination of aldose reductase inhibitors and probenecid for the treatment of diabetic complications |
KR20240034427A (ko) * | 2022-09-07 | 2024-03-14 | 애니머스큐어 주식회사 | 알도오즈 환원효소 억제제를 포함하는 근원 세포 증식 및 분화 촉진용 조성물 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4492706A (en) * | 1983-08-01 | 1985-01-08 | American Home Products Corporation | Method of lowering lipid levels |
US4939140A (en) * | 1985-11-07 | 1990-07-03 | Pfizer Inc. | Heterocyclic oxophthalazinyl acetic acids |
EP0310931A3 (de) * | 1987-10-08 | 1990-10-03 | Ethyl Corporation | Hühnerfutter |
FR2665440B1 (fr) * | 1990-07-31 | 1994-02-04 | Lipha | Nouveaux cycloalkylsulfonamides substitues, procedes de preparation et medicaments les contenant. |
US5064830A (en) * | 1990-08-02 | 1991-11-12 | Pfizer Inc. | Lowering of blood uric acid levels |
JP3049284B2 (ja) * | 1990-11-07 | 2000-06-05 | 株式会社三和化学研究所 | ヒダントイン誘導体並びにそれを有効成分とする糖尿病合併症及び循環器系疾患の予防及び治療剤 |
US5391551A (en) * | 1993-05-10 | 1995-02-21 | Pfizer Inc. | Method of lowering blood lipid levels |
US5834466A (en) * | 1994-12-22 | 1998-11-10 | The Regents Of The University Of California | Method for protecting of heart by limiting metabolic and ionic abnormalities developed during ischemia, following ischemia or resulting from ischemia |
CA2208485A1 (en) * | 1994-12-22 | 1996-06-27 | Ravichandran Ramasamy | Method for protecting the heart from ischemia |
IL118474A (en) * | 1995-06-01 | 2001-08-08 | Sankyo Co | Benzimideol derivatives and pharmaceutical preparations containing them |
-
1997
- 1997-02-20 US US08/803,301 patent/US6127367A/en not_active Expired - Fee Related
- 1997-02-20 IL IL12026497A patent/IL120264A0/xx not_active IP Right Cessation
- 1997-02-21 ES ES97301172T patent/ES2172748T3/es not_active Expired - Lifetime
- 1997-02-21 PT PT97301172T patent/PT792643E/pt unknown
- 1997-02-21 DE DE69711972T patent/DE69711972T2/de not_active Expired - Fee Related
- 1997-02-21 AT AT97301172T patent/ATE216239T1/de not_active IP Right Cessation
- 1997-02-21 EP EP97301172A patent/EP0792643B1/de not_active Expired - Lifetime
- 1997-02-21 DK DK97301172T patent/DK0792643T3/da active
- 1997-02-24 JP JP9039071A patent/JPH09316003A/ja active Pending
- 1997-02-26 CA CA002198564A patent/CA2198564C/en not_active Expired - Fee Related
- 1997-02-27 CN CN97102574A patent/CN1081460C/zh not_active Expired - Fee Related
- 1997-02-27 ZA ZA971717A patent/ZA971717B/xx unknown
- 1997-02-28 AU AU15010/97A patent/AU724327B2/en not_active Ceased
- 1997-02-28 KR KR1019970006780A patent/KR970061252A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU1501097A (en) | 1997-09-04 |
CN1081460C (zh) | 2002-03-27 |
ZA971717B (en) | 1998-08-27 |
JPH09316003A (ja) | 1997-12-09 |
MX9701533A (es) | 1998-06-30 |
CA2198564C (en) | 2000-06-27 |
CN1168794A (zh) | 1997-12-31 |
EP0792643B1 (de) | 2002-04-17 |
ATE216239T1 (de) | 2002-05-15 |
KR970061252A (ko) | 1997-09-12 |
CA2198564A1 (en) | 1997-08-29 |
ES2172748T3 (es) | 2002-10-01 |
PT792643E (pt) | 2002-08-30 |
EP0792643A1 (de) | 1997-09-03 |
DK0792643T3 (da) | 2002-07-22 |
DE69711972T2 (de) | 2002-08-29 |
US6127367A (en) | 2000-10-03 |
DE69711972D1 (de) | 2002-05-23 |
AU724327B2 (en) | 2000-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA971717B (en) | Method of reducing tissue damage associated with non-cardiac ischemia | |
AU3007897A (en) | High fluence diode laser device and method for the fabrication and use thereof | |
AU2467297A (en) | New benzimidazole derivatives with antihistaminic activity | |
AU3272995A (en) | Protective prostaglandins for use in conjunction with chemotherapeutic agents | |
CY2180B1 (en) | 2-(2Amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative | |
AU7553598A (en) | Ellipsometer with two lasers | |
PH27278A (en) | Spiro-isoquinoline-pyrrolidine tetrones useful as aldose reductase inhibitors | |
AU7697094A (en) | Turbo-machine with reduced attrition | |
AU5315498A (en) | Head for the linear dimension checking of mechanical pieces | |
AU2675299A (en) | Monitor support with self-positioning guide track | |
DE69020394D1 (de) | Aldose-Reductase-Inhibitor. | |
AU2654492A (en) | Method for checking the working condition of an optically operated proximity switch | |
AU1500997A (en) | Method of reducing tissue damage associated with ischemia | |
GB2277633B (en) | High power laser amplifier | |
AU6058694A (en) | Endoscope with retractable tool | |
GB2280538B (en) | Method for the prevention of eye damage when using high-power lasers | |
AU1436000A (en) | Auxiliary device for performing work above the head | |
AU2165897A (en) | Non-genetically modified mammal as a model for multiple sclerosis | |
AUPQ050599A0 (en) | Power actuated tool and shroud for use with the tool | |
AU2001290103A1 (en) | Methods for diagnosing and treating autosomal dominant optic atrophy | |
GB2266406B (en) | High-power laser source | |
SE9302552D0 (sv) | Vaeltningshindrande skenstyrning foer smaelgaangstruckar | |
TJ99000570A (en) | A method of plasty of the osteosoft-woven defects by the complex-compound scrap | |
KR940021472U (ko) | 모니터의 주전원 자동 온/오프 장치 | |
ITMI930136V0 (it) | Struttura di corpo illuminante con fascio luminoso rotante, particolarmente per veicoli e simili |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |